Abstract
Previous data showed that mesenchymal stem cells (MSC) improved the renal morphology and attenuated inflammation, microvascular rarefaction, fibrosis and proteinuria in the stenotic kidney induced by 2 Kidney‐1 clip (2K‐1C) model. Here we evaluated the effect of MSC on the contralateral kidney. Three weeks after left renal artery occlusion, fluorescently tagged MSC (2x105 cells/animal) were injected weekly into the tail vein of the 2K‐1C rats. Flow cytometry showed labeled MSC in the cortex and medulla of both kidneys. MSC significantly reduced blood pressure (BP) and proteinuria in 2K‐1C rats. Glomerular filtration rate (GFR) was reduced in the stenotic kidney and renal plasma flow (RPF) was diminishedin both kidneys. MSC treatment improved these parameters in both kidneys. Contralateral kidney presented altered medullary morphology, fibrosis and vascular loss and MSC improved the morphology and decreased the fibrotic areas. In contrast, the efficiency of MSC improving vascular rarefaction was not observed in the contralateral kidney. Thus, MSC therapy in the 2K‐1C model prevented the progressive increase of BP, improved renal function, morphology and reduced fibrosis in both stenotic and contralateral kidneys but it was more efficient improving vascular rarefaction in stenotic than in contralateral kidney. This therapy may be a promising strategy to treat renovascular hypertension and its renal consequences in the near future. Supported by CAPES.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
